Literature DB >> 16047221

Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism.

Patricio E Ray1, Angel A Soler-García, Lian Xu, Carl Soderland, Robert Blumenthal, Anu Puri.   

Abstract

A central question in the pathogenesis of HIV-associated thrombotic microangiopathic (HIV-TMA) lesions is whether the HIV-1 envelope glycoprotein (HIV-1 Env) can interact directly with human glomerular endothelial cells (HGECs) through specific HIV-1 co-receptors. The goal of this study was to determine whether cultured primary HGECs express significant levels of the major HIV-1 co-receptors CD4, CXCR4, and/or CCR5 to allow fusion interactions with HIV-1. The expression of CD4, CXCR-4 and CCR-5 was assessed in cultured HGECs by reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry using specific antibodies. The HIV-1 Env-mediated membrane fusion of target glomerular cells was evaluated by a fluorescent dye transfer-based cell-cell fusion microscopic method. HGECs express CXCR4 mRNA and protein as determined by RT-PCR and immunostaining with phycoerythrin-conjugated anti-CXCR4 Mab 12G5. CD4 and CCR5 were not detected in HGECs, either by RT-PCR or by surface immunostaining with specific antibodies. Incubation of HGECs with cells expressing a CD4-independent envelope strain (HIV-1IIIB-8x) and the CD4-dependent envelope strain (HIV-1IIIB) resulted in transfer of fluorescent dyes of approximately 20% after 8-16 h incubation at 37 degrees C. Incubation in the presence of inhibitors (C34, which blocks six-helix bundle formation, and AMD3100, which interacts with CXCR4) reduced dye transfer by 60%-80%, confirming that the dye transfer was specific with respect to gp120-gp41-mediated fusion. Cultured primary HGECs express CXCR4 but not CD4 or CCR5. The ability of HGECs to promote fusion by a CD4-independent HIV-1 envelope glycoprotein suggests that these cells may become a potential direct target of certain HIV-1 isolates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047221     DOI: 10.1007/s00467-005-1950-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  51 in total

1.  Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120.

Authors:  M B Huang; M Khan; M Garcia-Barrio; M Powell; V C Bond
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

2.  Up-regulation of Duffy antigen receptor expression in children with renal disease.

Authors:  X H Liu; T J Hadley; L Xu; S C Peiper; P E Ray
Journal:  Kidney Int       Date:  1999-04       Impact factor: 10.612

3.  Isoproterenol inhibits fibroblast growth factor-2-induced growth of renal epithelial cells.

Authors:  E B Izevbigie; J S Gutkind; P E Ray
Journal:  Pediatr Nephrol       Date:  2000-08       Impact factor: 3.714

4.  Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha.

Authors:  R Salcedo; K Wasserman; H A Young; M C Grimm; O M Howard; M R Anver; H K Kleinman; W J Murphy; J J Oppenheim
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

5.  HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases.

Authors:  C K Ullrich; J E Groopman; R K Ganju
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

6.  Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome.

Authors:  P E Ray; X H Liu; L Xu; T Rakusan
Journal:  Pediatr Nephrol       Date:  1999-09       Impact factor: 3.714

7.  HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells.

Authors:  Zeguang Ren; Qizhi Yao; Changyi Chen
Journal:  Lab Invest       Date:  2002-03       Impact factor: 5.662

8.  The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein.

Authors:  A Puri; P Hug; K Jernigan; J Barchi; H Y Kim; J Hamilton; J Wiels; G J Murray; R O Brady; R Blumenthal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children.

Authors:  M E Turner; K Kher; T Rakusan; L D'Angelo; S Kapur; D Selby; P E Ray
Journal:  Pediatr Nephrol       Date:  1997-04       Impact factor: 3.714

10.  Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells.

Authors:  P E Ray; G Aguilera; J B Kopp; S Horikoshi; P E Klotman
Journal:  Kidney Int       Date:  1991-10       Impact factor: 10.612

View more
  6 in total

Review 1.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  HIV-1 and kidney cells: better understanding of viral interaction.

Authors:  Joanna Mikulak; Pravin C Singhal
Journal:  Nephron Exp Nephrol       Date:  2010-04-21

3.  Shiga-like toxins and HIV-1 'go through' glycosphingolipids and lipid rafts in renal cells.

Authors:  Patricio E Ray
Journal:  Kidney Int       Date:  2009-06       Impact factor: 10.612

Review 4.  Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy.

Authors:  Patricio E Ray
Journal:  Pediatr Nephrol       Date:  2009-03-14       Impact factor: 3.714

5.  Hemorrhagic Stroke in an Adolescent Female with HIV-Associated Thrombotic Thrombocytopenic Purpura.

Authors:  Natella Rakhmanina; Edward Cc Wong; Jeremiah C Davis; Patricio E Ray
Journal:  J AIDS Clin Res       Date:  2014-06

6.  Circulating Fibroblast Growth Factor-2, HIV-Tat, and Vascular Endothelial Cell Growth Factor-A in HIV-Infected Children with Renal Disease Activate Rho-A and Src in Cultured Renal Endothelial Cells.

Authors:  Jharna R Das; J Silvio Gutkind; Patricio E Ray
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.